LGALS3 signaling and macrophage ferroptosis in steatohepatitis

Table 2 Evidence status and next-step validation of the proposed LGALS3-TRAF6-GPX4 framework

Domain/claim	Current support	Key gap	Priority next step	Translational impact
QWZG efficacy in experimental MASH	Improved histology, fibrosis-associated readouts, and oxidative/iron-stress indices in CDAHFD	Generalizability to obesity-linked disease settings is unknown	Validate efficacy and axis modulation in at least one obesity-associated model	External validity
LGALS3 as an upstream node	Macrophage-associated amplifier supported by the featured study and prior liver disease literature	Driver vs correlated marker remains unresolved in vivo	Myeloid/Kupffer cell-focused LGALS3 perturbation with rescue design	Target nomination
TRAF6-GPX4 linkage	TRAF6 inhibition supports directionality; external studies provide biochemical precedent	Direct regulation in hepatic macrophages is unproven	Cell-specific Traf6 manipulation plus GPX4 rescue or depletion	Mechanistic confidence
Macrophage ferroptosis as a disease layer	Ferroptosis is supported as an injury amplifier; Kupffer cell ferroptosis has experimental support	Dominant pathogenic cell compartment remains uncertain	Compare hepatocyte and macrophage ferroptosis readouts across models and time points	Actionable cell context
Kupffer cell necessity	Macrophage-line and whole-liver data are consistent with involvement	In vivo necessity is not established	Primary Kupffer cell validation and myeloid-compartment necessity testing	From plausibility to causality
Human relevance	The framework is biologically coherent and testable in human-oriented systems	Primary human Kupffer cell or PCLS confirmation is lacking	Validate in primary human Kupffer cells and/or precision-cut liver slices	Translational confidence
Formula-to-axis specificity	Pathway association is shown after QWZG exposure	Active constituents, direct targets, and composition-function linkage remain undefined	Potency-linked constituent prioritization and Q-marker construction	CMC readiness
Clinical development readiness	The axis offers an exploratory pharmacodynamic framework	No validated thresholds, positioning strategy, or interaction package	Develop exploratory biomarker assays plus add-on/sequence and safety plans	Clinical positioning

CDAHFD: Choline-deficient, L-amino acid-defined high-fat diet; CMC: Chemistry, manufacturing, and controls; MASH: Metabolic dysfunction-associated steatohepatitis; PCLS: Precision-cut liver slices; Q-marker: Quality marker.